News - Copaxone


Current filters:


Popular Filters

MS therapeutics market led by Copaxone


The multiple sclerosis (MS) therapeutics market has been forecast to increase at a compound annual growth…

CopaxoneMarkets & MarketingNeurologicalPharmaceuticalTeva Pharmaceutical Industries

Teva Pharma sees slowdown in generic revenues


Israel-based Teva Pharmaceutical Industries (NYSE: TEVA), the world largest generics firm but with a…

CopaxoneFinancialGenericsPharmaceuticalTeva Pharmaceutical Industries

Court ruling favors Mylan in Copaxone patent dispute


A US court has dismissed claims that US generic drugmaker Mylan (Nasdaq: MYL) infringed four patents…

CopaxoneGenericsMomenta PharmaceuticalsMylan LaboratoriesNatco PharmaNeurologicalNorth AmericaPatentsSandozTeva Pharmaceutical Industries

Teva fleshes out restructuring plan; licenses Xenon pain drug for $376 million


Teva Pharmaceutical Industries (NYSE: TEVA's new chief executive Jeremy Levin has outlined the company's…

CopaxoneFinancialGenericsLicensingPatentsPharmaceuticalResearchTeva Pharmaceutical IndustriesXenon Pharmaceuticals

Teva gets favorable UK Copaxone patent ruling


Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) says that the UK High Court of Justice issued…

CopaxoneEuropeGenericsLegalMylan LaboratoriesNeurologicalPatentsPharmaceuticalTeva Pharmaceutical Industries

Back to top